Full-Time

Clinical Scientist

Ophthalmology

Deadline 10/7/26
Sanofi

Sanofi

10,001+ employees

Global pharma company; vaccines and R&D

Compensation Overview

$148.5k - $214.5k/yr

Cambridge, MA, USA + 2 more

More locations: Washington, DC, USA | Morristown, NJ, USA

In Person

Master's, PharmD, PhD, MD

Category
Biology & Biotech (1)
Required Skills
Risk Management
Data Analysis

Get referred to Sanofi

See people who can refer or advise you

Requirements
  • A Master's degree is required in Biomedical Science, Life Sciences, Pharmaceutical Sciences, or a related scientific field.
  • At least 3 years of industry experience in clinical research and/or drug development is required.
  • Experience in ophthalmology clinical trials is required.
  • The candidate must understand data collection, data flow, data validation, medical validation, medical review processes, data analysis, and clinical relevance.
  • The candidate must be able to develop quality management practices and guidelines for medical data review using data-driven and risk-management approaches.
  • The candidate must have a digital and data-oriented mindset.
  • The candidate must be proficient in clinical literature and critical interpretation of clinical study results.
  • The candidate must have experience supporting the preparation and execution of clinical trials.
  • The candidate must have experience with basic statistical principles and techniques of data analysis, interpretation, and clinical relevance.
  • The candidate must have knowledge of translational medicine and biomarkers.
  • The candidate must be able to take responsibility for medical activities and independently endorse Clinical Research Director decisions.
  • The candidate must have experience collaborating with cross-functional, interdisciplinary global teams and communicating with investigators, vendors, and contract research organizations.
  • The candidate must be able to manage multiple tasks, prioritize effectively, and work autonomously.
  • The candidate must have problem-solving, conflict-resolution, and decision-making skills, including the ability to anticipate and escalate issues proactively and define action plans.
Responsibilities
  • Ensure scientific support for ophthalmology studies by operationalizing the medical validation and review plan, including reports and trackers.
  • Support the design and execution of multiple clinical studies within the ophthalmology development plan.
  • Perform clinical review and analysis of data listings, patient profiles, and essential study data within statistical reports, and partner with Data Management to generate relevant queries.
  • Participate in Case Report Form design and review Case Report Form design and completion instructions.
  • Support the Clinical Research Director and Study Team with study start-up, site opening, enrollment monitoring, and study support.
  • Contribute to the preparation and review of study documents requiring scientific background, including submission portfolios, protocols, amended protocols, patient written information, presentations, study plans, study reports, and trial disclosure forms.
  • Support preparation of clinical-trial documents, including protocols, informed consent, and benefit-risk assessments.
  • Support the Clinical Research Director in preparing medical responses to questions from Health Authorities, Institutional Review Boards, Ethics Committees, investigators, and study experts.
  • Support regulatory document filing and archiving.
  • Contribute to the centralized monitoring strategy in consistency with the planned statistical analysis.
  • Support study-data validation and review processes, including clinical case review of safety events reported to Pharmacovigilance or safety events of special interest.
  • Ensure the quality and currency of study documents and the adequacy of Case Report Forms with protocols and protocol amendments.
  • Help rationalize and document data-collection needs quantitatively and qualitatively.
  • Help prepare, organize, conduct, and document minutes for Study Committees, including Independent Data Monitoring Committees.
  • Support the Clinical Research Director in organizing and leading Steering Committees, Data Monitoring Committees, and Adjudication Committee meetings.
  • Follow contracts with business support.
  • Participate in Study Team and monitoring-team training on medical information.
  • Maintain scientific, technical, and clinical expertise in ophthalmology.
  • Critically read and evaluate relevant literature and understand data and the status of competitive products.
  • Provide clinical landscape and benchmark updates.
  • Build and maintain internal and external collaborations with opinion leaders and investigators.
  • Support interactions with internal governance bodies, external partners, key opinion leaders, investigators, and committees.
  • Assess and provide cost elements related to study support in collaboration with the Study Team, including planning management.
  • Work along agreed timelines and support study activities as a performance-oriented individual.
Desired Qualifications
  • A PhD, PharmD, or MD in Biomedical Science, Life Sciences, Pharmaceutical Sciences, or a related scientific field is preferred.
  • Experience with gene therapy or novel therapeutic modalities in ophthalmology.
  • Familiarity with retinal diseases, age-related macular degeneration, geographic atrophy, or other ophthalmology indications.
  • Experience with audit responses and regulatory inspections.

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 sales rose 17.8%; Dupixent topped €5.2 billion for the quarter.
  • July 30 upgraded 2026 guidance to around 10% sales growth, with higher EPS.
  • August 4 MenQuadfi infant approval widens vaccine reach; Nexviazyme's June phase 3 readout strengthens pipeline.

What critics are saying

  • Dupixent faces tougher H2 2026 comparisons, threatening growth after the €5.2 billion quarter.
  • Cenrifki carries liver injury risk; strict monitoring can slow adoption and invite liability.
  • Dupixent concentration and Regeneron's November 2024 lawsuit threaten Sanofi's core growth engine.

What makes Sanofi unique

  • Dupixent and partnered launch engine generate repeatable immunology cash flows across geographies.
  • Sanofi converted 2026 approvals for Sarclisa Escena, Wayrilz, and Cenrifki into launches.
  • Paulo Fontoura's September 1 R&D mandate centralizes translational science and regulatory execution.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Business Wire
Aug 13th, 2026
Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Epicrispr Biotechnologies Closes $90 Million Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Morningstar
Aug 12th, 2026
InduPro raises $77M Series B, doses first patient in Phase 1 trial of bispecific ADC for lung cancer

InduPro has closed a $77 million Series B financing round and dosed its first patient in a Phase 1 study of IDP-001, its lead oncology programme. The biotechnology company is developing IDP-001, a bispecific antibody-drug conjugate targeting EGFR and a novel tumour-associated proximity antigen, for treating advanced squamous non-small cell lung cancer and other solid tumours. The Column Group led the financing round, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company. Proceeds will support Phase 1 clinical development and early proof-of-concept data generation for IDP-001, whilst advancing InduPro's broader preclinical pipeline. InduPro uses a proximity-guided platform to map protein spatial relationships on cell surfaces for discovering selective co-target pairs.

FinancialContent
Jul 24th, 2026
Scribe Therapeutics prices upsized $129M IPO at top of range

Scribe Therapeutics, a clinical-stage biotechnology company developing in vivo CRISPR technologies, has priced its upsized initial public offering at $15.00 per share, the high end of its range. The company is offering 8,580,000 shares, expecting to raise $128.7 million in gross proceeds before fees and expenses. Scribe has also granted underwriters a 30-day option to purchase up to 1,287,000 additional shares. The shares are expected to begin trading on the Nasdaq Global Market on 24 July 2026 under the ticker symbol "SCTX", with the offering closing on 27 July 2026. Additionally, Scribe has agreed to sell 500,000 shares at the same price to Sanofi in a concurrent private placement. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities are serving as joint book-running managers.

Associated Press
Jul 10th, 2026
Sanofi's Sarclisa Escena approved in US as first anticancer drug delivered via on-body injector

The US Food and Drug Administration has approved Sanofi's subcutaneous Sarclisa Escena for treating multiple myeloma, making it the first anticancer treatment administered through an on-body injector. The therapy uses Enable Injections' CirCLIQ device, which delivers the drug automatically with a retractable 30g needle. The approval was supported by the IRAKLIA phase 3 study, which demonstrated that Sarclisa Escena delivered via the on-body injector provided similar efficacy and safety compared to intravenous infusion, with significantly shorter treatment time and fewer infusion-related reactions. The study showed a 71.1% objective response rate in patients with relapsed or refractory multiple myeloma. More than 70,000 patients worldwide have been treated with Sarclisa-based regimens. The on-body injector aims to reduce physical burden on healthcare providers whilst offering patients greater convenience during treatment.

Yahoo Finance
Jul 5th, 2026
Sanofi appoints Paulo Fontoura as R&D chief to accelerate pharma pipeline transformation

Sanofi has appointed Paulo Fontoura as Executive Vice President and Global Head of Research & Development Pharma, effective 1 September. Based in Paris, Fontoura will oversee the company's innovation engine, spanning research, translational medicine, clinical development, and regulatory affairs. He succeeds Dr Houman Ashrafian, who is leaving to pursue new opportunities. Fontoura brings over 25 years of experience across academic medicine, translational science, and pharmaceutical innovation. The appointment comes as Sanofi drives an R&D transformation whilst progressing its pipeline across multiple therapeutic areas. Separately, MacroGenics confirmed it will receive $24.5 million in regulatory milestone payments from Sanofi following FDA accelerated approval of TZIELD to delay decline in endogenous insulin production in children. Sanofi is a global biopharmaceutical company focusing on immunology, rare diseases, and oncology.